Alligator Bioscience announced that it plans to adjust the size of its organization to reflect the end of the resource-intensive OPTIMIZE-1 Phase 2 clinical trial with its lead asset mitazalimab, and the need for the company to prioritize its preclinical and early-stage assets. The planned restructuring remains subject to negotiation with the relevant trade unions but would result in a reduction of approximately 20-25% of the current workforce, which once implemented is expected to reduce operational cash burn with SEK 20 million annually. Alligator will notify the Swedish Public Employment Service (Sw.

Arbetsförmedlingen) and seek consultations with trade unions regarding the reorganization. Decisions regarding employee reductions will take place after the change consultations have been concluded according to local regulations.